Literature DB >> 8626005

Measles immunity and response to revaccination among secondary school children in Cumbria.

N Calvert1, F Cutts, R Irving, D Brown, J Marsh, E Miller.   

Abstract

The prevalence of antibody to measles virus in 759 children aged 11-18 years attending a secondary school in Cumbria was measured using a salivary IgG antibody capture assay. Serum IgG antibody levels were measured using a plaque reduction neutralization assay in subjects whose saliva was antibody negative. Vaccination histories were obtained from the child health computer and general practice record. A total of 662 pupils (87% of those tested) had detectable measles-specific IgG in saliva. Of the remaining 97, 82 provided blood samples and 29 had serum neutralizing antibody levels above 200 mIU/ml. Afer adjusting for non-participation rates, the proportion considered non-immune (no IgG in saliva and < or = 200 mIU/ml in serum) was 9% overall, ranging from 6% in vaccinated children to 20% in unvaccinated children. Measles-mumps-rubella vaccine was given to 50 children of whom 38 provided post-vaccination serum and 32 saliva samples. Thirty (79%) had a fourfold or greater rise in serum neutralizing antibody and 28 (88%) developed IgG antibody in saliva. Half of the children considered non-immune by antibody testing would have been overlooked in a selective vaccination programme targeted at those without a history of prior vaccination. A programme targeted at all school children should substantially reduce the proportion non-immune since a primary or booster response was achieved in three quarters of previously vaccinated children with low antibody levels and in all unvaccinated children. While it is feasible to screen a school-sized population for immunity to measles relatively quickly using a salivary IgG assay, a simple inexpensive field assay would need to be developed before salivary screening and selective vaccination could substitute for universal vaccination of populations at risk of measles outbreaks. The salivary IgG assay provided a sensitive measure of a booster response to vaccination.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8626005      PMCID: PMC2271248          DOI: 10.1017/s0950268800058969

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  21 in total

1.  Measles antibody: reevaluation of protective titers.

Authors:  R T Chen; L E Markowitz; P Albrecht; J A Stewart; L M Mofenson; S R Preblud; W A Orenstein
Journal:  J Infect Dis       Date:  1990-11       Impact factor: 5.226

2.  Further-attenuated measles vaccine: virus passages affect viral surface protein expression, immunogenicity and histopathology pattern in vivo.

Authors:  O A Sinitsyna; O E Khudaverdyan; L L Steinberg; F G Nagieva; V D Lotte; L V Dorofeeva; E E Rozina
Journal:  Res Virol       Date:  1990 Sep-Oct

3.  Measles, mumps, and rubella vaccine: time for a two stage policy?

Authors:  H Carter; D Gorman
Journal:  BMJ       Date:  1992-03-07

4.  Measles, mumps, and rubella vaccination.

Authors:  A Hill
Journal:  BMJ       Date:  1992-03-21

5.  The 1st International Standard for anti-measles serum.

Authors:  T Forsey; A B Heath; P D Minor
Journal:  Biologicals       Date:  1991-07       Impact factor: 1.856

6.  Interpretation of serological surveillance data for measles using mathematical models: implications for vaccine strategy.

Authors:  N J Gay; L M Hesketh; P Morgan-Capner; E Miller
Journal:  Epidemiol Infect       Date:  1995-08       Impact factor: 2.451

7.  Persistence of measles antibody after revaccination.

Authors:  L E Markowitz; P Albrecht; W A Orenstein; S M Lett; T J Pugliese; D Farrell
Journal:  J Infect Dis       Date:  1992-07       Impact factor: 5.226

8.  Detection of measles, mumps, and rubella antibodies in saliva using antibody capture radioimmunoassay.

Authors:  K R Perry; D W Brown; J V Parry; S Panday; C Pipkin; A Richards
Journal:  J Med Virol       Date:  1993-07       Impact factor: 2.327

9.  Role of virus strain in conventional and enhanced measles plaque neutralization test.

Authors:  P Albrecht; K Herrmann; G R Burns
Journal:  J Virol Methods       Date:  1981-12       Impact factor: 2.014

10.  Measles antibody: comparison of long-term vaccination titres, early vaccination titres and naturally acquired immunity to and booster effects on the measles virus.

Authors:  B Christenson; M Böttiger
Journal:  Vaccine       Date:  1994-02       Impact factor: 3.641

View more
  2 in total

1.  Microparasite population dynamics and continuous immunity.

Authors:  L J White; G F Medley
Journal:  Proc Biol Sci       Date:  1998-10-22       Impact factor: 5.349

2.  Measles virus-specific antibody levels in individuals in Argentina who received a one-dose vaccine.

Authors:  Marcelo H Argüelles; Mariana L Orellana; Alejandro A Castello; Guillermo A Villegas; Matilde Masini; Alejandra L Belizan; Silvia González Ayala; Osmar D Vera; Graciela Glikmann
Journal:  J Clin Microbiol       Date:  2006-08       Impact factor: 5.948

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.